



New Advances and Challenges in Multiple Sclerosis: Pathophysiology and Therapeutic Strategies

Guest Editor:

Dr. Diego Clemente

Neuroimmuno-Repair Group,
National Hospital for
Paraplegics, Toledo, Spain

Deadline for manuscript
submissions:

closed (30 June 2022)

Message from the Guest Editor

Multiple sclerosis (MS) is the most common neurological disease, being especially dramatic for debuting mainly in young adults and for not having a cure. The treatments address the immune component of the disease, are mostly effective in the relapsing-remitting MS variant, and are almost totally ineffective in the progressive forms of MS. Therefore, the search for molecular/cellular factors capable of differentiating at the pathophysiological level the intrinsic reasons for these differences, is of vital importance in the search for new treatments for people with MS. On the other hand, the existence of recovery phases in RRMS patients points to the existence of spontaneous self-correcting phenomena of the inflammatory episode that lead to neuro-repair of the damaged tissue. The aim of this Special Issue of Biomedicines is to provide an overview of the pathophysiologic role of newer and older molecular mechanisms of MS together with the presentation of insights for the consecution of new therapeutic strategies. Moreover, it will focus on biomarkers to help in the accurate disease monitoring. Both original articles and reviews will be considered for publication in this Issue.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)